Asahi Kasei Medical
  • Site Map
  • Contact Us
  • Font size: Small
  • Font size: Medium
  • Font size: Large
  • Home
  • Our Approach to Business
  • Corporate Information
  • News
  • Products
  • Patients and Families

References by Diseases

Literature about conditions for therapeutic apheresis is indicated.

Nephrology

ABO- / HLA-incompatible kidney transplantation

Tanabe K.
Japanese experience of ABO-incompatible living kidney transplantation.
Transplantation. 84:S4-7, 2007.
Hirai et al.
Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection.
Transpl Int. 25:925-34, 2012.

Top of page

Gastroenterology references

Inflammatory bowel disease (IBD)

Nagase et al.
Complications of Leukocytapheresis.
Ther Apher. 2:120-4, 1998.
Kosaka et al.
Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease.
Intern Med. 38:102-11, 1999.
Hidaka et al.
Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis.
J Clin Apheresis. 16:74-81, 2001.
Yamaji et al.
Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers.
Ther Apher. 6:402-12, 2002.
Sawada et al.
Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column.
Current Pharmaceutical Design 9:307-21, 2003.
Fukunaga et al.
Poorly controlled ulcerative colitis treated by colectomy during remission induced by extracorporeal leukocyte removal therapy.
J Gastroenterol. 38:684-9, 2003.
Kohgo et al.
Leukocytapheresis for treatment of IBD.
J Gastroenterol. 38 Suppl 15:51-4, 2003.
Sawada K.
Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease.
Dis Colon Rectum. 46 Suppl: S66-77, 2003.
Andoh et al.
Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis.
J Gastroenterol. 39:1150-7, 2004.
Klingel et al.
Leukocytapheresis (LACP) for chronic active ulcerative colitiss - final results of a pilot trial and design of the german randomized, double-blind, placebo-controlled multicenter trial (MICELL-UC trial).
J Clinic Apheresis 20, Abs 4, 2005.
Sawada et al.
Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.
Am J Gastroenterol. 100:1362-9, 2005.
Sawada et al.
Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon.
Dig Dis Sci. 50:767-73, 2005.
Ashizuka et al.
Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.
Ther Apher Dial. 10:54-8, 2006.
Sandborn WJ.
Preliminary data on the use of apheresis in inflammatory bowel disease.
Inflamm Bowel Dis. 12 Suppl 1:S15-21, 2006.
Matsumoto et al.
Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study.
Ther Apher Dial. 12:484-90, 2008.
Dittrich et al.
Leukocytapheresis in a girl with severe ulcerative colitis refractory to corticosteroids, infliximab, and cyclosporine A.
Inflamm Bowel Dis. 14:1466-7, 2008.
Mitsuyama et al.
Mobilization of bone marrow cells by leukocytapheresis in patients with ulcerative colitis.
Ther Apher Dial. 12:271-7, 2008.
Mitsuyama et al.
Recent understanding of leukocytapheresis (LCAP) for the treatment of inflammatory bowel disease.
Curr Pharm Des. 15:2110-9, 2009.
Mitsuyama et al.
Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action.
Cytotherapy. 11:229-37, 2009.
Muratov et al.
Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study.
J Clin Apher. 25:287-93, 2010.
Ashida et al.
A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis.
Transfus Apher Sci. 44:113-7, 2011.
Fukunaga et al.
Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis.
J Clin Apher. 26:326-31, 2011.
Okuyama et al.
Multicenter prospective study for clinical and endoscopic efficacies of leukocytapheresis therapy in patients with ulcerative colitis.
Scand J Gastroenterol. 48:412-8, 2013.

Bilirubin

Senf et al.
Bilirubin-adsorption in 23 critically ill patients with liver failure.
Int J Artif Organs. 27:717-22, 2004.
Adani et al.
Selective bilirubin removal by plasma treatment with Plasorba BR-350 for early cholestatic graft dysfunction.
Transplant Proc. 39:1904-6, 2007.
Krawczyk et al.
Prolonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanalicular phospholipid and bile salt transporters.
Ann Hepatol. 11:710-4, 2012.

HCV

Ohara et al.
Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
Hepatogastroenterology. 58:133-6, 2011.
Sugimoto et al.
Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy.
Dig Dis. 31:434-9, 2013.

Top of page

Rheumatology references

Systemic lupus erythematosus (SLE)

Liang et al.
Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.
Arthritis and Rheumatism, vol. 32, No. 9, 1989.
Gaubitz et al.
Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus.
J Autoimmun. 11:495-501, 1998.
Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus.
Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus.
Arthritis and Rheumatism, vol. 50, No. 11, 2004.
Sugimoto et al.
Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis.
Ther Apher Dial. 10:187-92, 2006.
Yamaji et al.
Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroid-resistant lupus nephritis.
Ther Apher Dial. 12:298-305, 2008.
Loo et al.
Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis.
Transfus Apher Sci. 43:335-40, 2010.
Liu et al.
Successful treatment of patients with systemic lupus erythematosus complicated with autoimmune thyroid disease using double-filtration plasmapheresis: a retrospective study.
J Clin Apher. 26:174-80, 2011.

Rheumatoid arthritis (RA)

Inoh et al.
Randomized Open Trial to Compare the Effectiveness of Cryofiltration and Leukapheresis in Methotrexate-Resistant RA patients.
Jpn J Apheresis 16:189-190, 1997.
Sueoka A.
Therapeutic apheresis application using membrane plasma fractionation technology: present scope and limitations.
Ther Apher. 4:211-2, 2000.
Matsuda et al.
Double filtration plasmapheresis for the treatment of a rheumatoid arthritis patient with extremely high level of c-reactive protein.
Ther Apher Dial. 8:404-8, 2004.
Yu et al.
A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis.
J Clin Rheumatol. 13:193-8, 2007.

Top of page

Cardiovascular references

Familial hypercholesterolemia

Geiss et al.
Low density lipoprotein apheresis by membrane differential filtration (Cascade filtration).
Therapeutic Apheresis. 3:199-202, 2000.
Julius et al.
Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP.
Int J Artif Organs. 25:1180-8, 2002.
Klingel et al.
From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis.
Ther Apher Dial. 7:350-8, 2003.
Klingel et al.
Lipidfiltration - safe and effective methodology to perform lipid-apheresis.
Transfusion and Apheresis Science. 30:245-254, 2004.
Julius et al.
Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance characteristics with DALI and Lipidfiltration.
J Clin Apher. 22:215-23, 2007.
Leebmann et al.
Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study.
Circulation. 128:2567-76, 2013.

Top of page

Neurology references

Myasthenia gravis (MG)

Splendiani et al.
Plasmaperfusion on triptophan columns can improve the clinical outcome of patients affected with myasthenia gravis.
Artif Cells Blood Substit Immobil Biotechnol. 31:69-79, 2003.
Chiu et al.
Pulmonary function study of myasthenia-gravis patients treated with double filtration plasmapheresis.
J Clin Apher. 18:125-8, 2003.
Wagner et al.
[Long-term treatment of refractory myasthenia gravis with immunoadsorption].
Dtsch Med Wochenschr. 133:2377-82, 2008. German.
Nagane et al.
Early aggressive treatment strategy against myasthenia gravis.
Eur Neurol. 65:16-22, 2011.
Köhler et al.
A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.
J Clin Apher. 26:347-55, 2011.

Guillain-Barré syndrome (GBS)

Haupt et al.
Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome.
Ther Apher. 4:198-200, 2000.
Seta et al.
Factors influencing outcome in Guillain-Barré Syndrome: comparison of plasma adsorption against other treatments.
Clin Neurol Neurosurg. 107:491-6, 2005.
Arakawa et al.
Immunoadsorption therapy for a child with Guillain-Barre syndrome subsequent to Mycoplasma infection: a case study.
Brain Dev. 27:431-3, 2005.

Chronic inflammatory demyelinating polyneuropathy (CIDP)

Galldiks et al.
Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment.
Eur Neurol. 66:183-9, 2011.

Multiple sclerosis (MS)

Noseworthy et al.
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis.
Neurology. 56:1514-22, 2001.
Ramunni et al.
A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis.
Ther Apher Dial. 12:250-4, 2008.
Mauch et al.
[Immunoadsorption for steroid-unresponsive multiple sclerosis-relapses : Clinical data of 14 patients].
Nervenarzt. 82:1590-5, 2011. German
Trebst et al.
Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis.
Blood Purif. 33:1-6, 2012.
Koziolek et al.
Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis.
J Neuroinflammation. 26;9:80, 2012.
Koziolek et al.
Immunoadsorption in steroid-refractory multiple sclerosis.
Atheroscler Suppl. 14:175-8, 2013.
Heigl et al.
Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients.
Atheroscler Suppl. 14:167-73, 2013.

Top of page

Hematology references

Multiple myeloma (MM)

El-Achkar et al.
Approach to acute renal failure with multiple myeloma: role of plasmapheresis.
Ther Apher Dial. 9:417-22, 2005.

Thrombotic thrombocytopenic purpura (TTP)

Kawano et al.
Therapeutic modality of 11 patients with TTP in a single institution in Miyazaki from 2000 to 2011.
Intern Med. 52:1883-91, 2013.

Top of page

Dermatology references

Pemphigus

Herrero-González et al.
Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption.
Clin Exp Dermatol. 30:519-22, 2005.

Top of page

Ophthalmology references

Age-related macular degeneration (AMD)

Brunner et al.
Influence of membrane differential filtration on the natural course of age-related macular degeneration: a randomized trial.
Retina 20:483-91, 2000.
Klingel et al.
Rheopheresis for age-related macular degeneration: a novel indication for therapeutic apheresis in ophthalmology.
Ther Apher. 6:271-81, 2002.
Klingel et al.
Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine.
Transfus Apheresis Sci. 29:71-84, 2003.
Pulido et al.
Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD).
J Clin Apheresis. 20:185-194, 2005.
Koss et al.
Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART.
Graefes Arch Clin Exp Ophthalmol. 247:1297-306, 2009.

Top of page

Otolaryngology references

Sudden sensorineural hearing loss (SSHL)

Mösges et al.
Quality of life in patients with idiopathic sudden hearing loss: comparison of different therapies using the Medical Outcome Short Form (36) Health Survey questionnaire.
Otol Neurotol. 29:769-75, 2008.
Klingel et al.
Rheopheresis for sudden sensorineural hearing loss.
Atheroscler Suppl. 10:102-6, 2009.

Top of page

Contact Us

Please feel free to send us any questions you may have about our products and support.

Contact Us

Your Voice

Share your feelings and experiences when using our products.

Your Voice
Note: It might be required in your country that medical devices shall be officially registered and/or approved by an authorized organization. Please contact our representative in your region or contact us to confirm whether the listed products are approved for use. These information may contain general information on medical-related topics and is not meant to provide specialist advice or instructions concerning the products and services sold by Asahi Kasei Medical. Please contact us directly for special inquiries. You should not use this information for diagnosing a health problem or disease but should always consult your own physician.Contact us

Top of page